Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351987 | 0.92 | IKBKB (0.41) | IKBKBMAP3K14NOTUMDRD1HSD17B10 | |
| SCHEMBL2351250 | 0.88 | NPC1 (0.40) | IKBKBMAP3K14NOTUMDRD1CHEK1 | |
| SCHEMBL2352712 | 0.87 | PTGES (0.43) | IKBKBMAP3K14NOTUMCHEK1AKT2 | |
| SCHEMBL2350128 | 0.84 | IKBKB (0.39) | IKBKBMAP3K14NOTUMDRD1HSD17B10 | |
| SCHEMBL2347368 | 0.81 | CYP11B1 (0.39) | IKBKBMAP3K14NOTUMCHEK1AKT2 | |
| SCHEMBL2353154 | 0.80 | APEX1 (0.44) | IKBKBMAP3K14NOTUMCHEK1AKT2 | |
| SCHEMBL2355006 | 0.80 | KCNQ3 (0.42) | IKBKBMAP3K14NOTUMDRD1HSD17B10 | |
| SCHEMBL2352347 | 0.80 | ALOX12 (0.42) | DRD1HSD17B10CSF1R | |
| SCHEMBL2350537 | 0.80 | PSD (0.36) | IKBKBMAP3K14NOTUMDRD1HSD17B10 | |
| SCHEMBL2351989 | 0.79 | PSD (0.40) | IKBKBMAP3K14NOTUMDRD1PSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1767529-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, CYP4Z1 | IKBKB 3721/4885MAP3K14 1317/4885NOTUM 2466/4885 |
| US-20090281337-A1 | Pyridazine compound and use thereof | PLPBP, PNPO, CYP4Z1 | IKBKB 3721/4885MAP3K14 1317/4885NOTUM 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.